$2.6T
Total marketcap
$169.6B
Total volume
BTC 49.99%     ETH 15.84%
Dominance

Recursion Pharmaceuticals RXRX Stock

11.42 USD {{ price }} 1.782530% {{change_pct}}%
Exchange
NasdaqGS
Market Cap
2.68B USD
LOW - HIGH [24H]
11.17 - 12.35 USD
VOLUME [24H]
11.28M USD
{{ volume }}
P/E Ratio
0
Earnings per share
-1.58 USD

Recursion Pharmaceuticals Price Chart

Recursion Pharmaceuticals RXRX Financial and Trading Overview

Recursion Pharmaceuticals stock price 11.42 USD
Previous Close 9.86 USD
Open 9.67 USD
Bid 0 USD x 800
Ask 0 USD x 800
Day's Range 9.05 - 9.79 USD
52 Week Range 4.54 - 14.18 USD
Volume 1.87M USD
Avg. Volume 1.97M USD
Market Cap 1.79B USD
Beta (5Y Monthly) -0.422964
PE Ratio (TTM) N/A
EPS (TTM) -1.58 USD
Forward Dividend & Yield N/A (N/A)
Ex-Dividend Date N/A
1y Target Est 14.43 USD

RXRX Valuation Measures

Enterprise Value 1.48B USD
Trailing P/E N/A
Forward P/E -5.8125
PEG Ratio (5 yr expected) -0.59
Price/Sales (ttm) 38.35303
Price/Book (mrq) 4.155496
Enterprise Value/Revenue 31.656
Enterprise Value/EBITDA -5.981

Trading Information

Recursion Pharmaceuticals Stock Price History

Beta (5Y Monthly) -0.422964
52-Week Change 22.04%
S&P500 52-Week Change 20.43%
52 Week High 14.18 USD
52 Week Low 4.54 USD
50-Day Moving Average 6.83 USD
200-Day Moving Average 8.64 USD

RXRX Share Statistics

Avg. Volume (3 month) 1.97M USD
Avg. Daily Volume (10-Days) 2.2M USD
Shares Outstanding 184.64M
Float 134.97M
Short Ratio 6.16
% Held by Insiders 7.45%
% Held by Institutions 86.30%
Shares Short 18.46M
Short % of Float 16.21%
Short % of Shares Outstanding 9.59%

Dividends & Splits

Trailing Annual Dividend Rate 0
Trailing Annual Dividend Yield 0%
5 Year Average Dividend Yield N/A
Payout Ratio 0
Last Split Factor

Financial Highlights

Fiscal Year

Fiscal Year Ends December 31, 2022
Most Recent Quarter (mrq) March 31, 2023
Next Fiscal Year End December 31, 2023

Profitability

Profit Margin 0%
Operating Margin (ttm) -556.58%
Gross Margin 0%
EBITDA Margin 0%

Management Effectiveness

Return on Assets (ttm) -23.83%
Return on Equity (ttm) -53.87%

Income Statement

Revenue (ttm) 46.64M USD
Revenue Per Share (ttm) 0.26 USD
Quarterly Revenue Growth (yoy) 127.49%
Gross Profit (ttm) -164128000 USD
EBITDA -246894000 USD
Net Income Avi to Common (ttm) -248824000 USD
Diluted EPS (ttm) -1.36
Quarterly Earnings Growth (yoy) N/A

Balance Sheet

Total Cash (mrq) 473.14M USD
Total Cash Per Share (mrq) 2.46 USD
Total Debt (mrq) 53.05M USD
Total Debt/Equity (mrq) 12.33 USD
Current Ratio (mrq) 5.34
Book Value Per Share (mrq) 2.238

Cash Flow Statement

Operating Cash Flow (ttm) -234228000 USD
Levered Free Cash Flow (ttm) -141951376 USD

Profile of Recursion Pharmaceuticals

Country United States
State UT
City Salt Lake City
Address 41 South Rio Grande Street
ZIP 84101
Phone 385 269 0203
Website https://www.recursion.com
Industry Biotechnology
Sector(s) Healthcare
Full Time Employees 500

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 1b/2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer; REC-64151 for the treatment of immune checkpoint resistance; and Anti-PD-(L)1, an orally bioavailable small molecule to improve sensitivity to immune checkpoint inhibitors in non-small cell lung cancer and additional tumors. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Chromaderm, Inc.; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.

Q&A For Recursion Pharmaceuticals Stock

What is a current RXRX stock price?

Recursion Pharmaceuticals RXRX stock price today per share is 11.42 USD.

How to purchase Recursion Pharmaceuticals stock?

You can buy RXRX shares on the NasdaqGS exchange. Contact your financial advisor to select a broker.

What is the ticker symbol for Recursion Pharmaceuticals?

The stock symbol or ticker of Recursion Pharmaceuticals is RXRX.

Which industry does the Recursion Pharmaceuticals company belong to?

The Recursion Pharmaceuticals industry is Biotechnology.

How many shares does Recursion Pharmaceuticals have in circulation?

The max supply of Recursion Pharmaceuticals shares is 234.65M.

What is Recursion Pharmaceuticals Price to Earnings Ratio (PE Ratio)?

Recursion Pharmaceuticals PE Ratio is now.

What was Recursion Pharmaceuticals earnings per share over the trailing 12 months (TTM)?

Recursion Pharmaceuticals EPS is -1.58 USD over the trailing 12 months.

Which sector does the Recursion Pharmaceuticals company belong to?

The Recursion Pharmaceuticals sector is Healthcare.

Recursion Pharmaceuticals RXRX included in indexes

Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
{{ item.name }} {{ item.symbol }} {{ item.price }} {{ item.price_usd }}
{{ item.change_pct }}
{{ item.volume }} {{ item.volume_usd }} {{ item.low }} {{ item.low_usd }} {{ item.high }} {{ item.high_usd }} {{ item.components_count }} {{ item.volume }} {{ item.volume_usd }}
NASDAQ Composite IXIC 16103.45 USD
+0.82
4.52B USD 16094.17 USD 16247.59 USD 4.52B USD
NASDAQ Biotechnology NBI 4337.34 USD
-0.65
4335.84 USD 4376.86 USD
NASDAQ HealthCare IXHC 986.88 USD
-0.25
986.44 USD 994.67 USD
NASDAQ Global Select Market Com NQGS 7837.41 USD
+0.85
7832.7 USD 7908.95 USD
Stlmt ID NASDAQ Biotechnology NBX 4604.4 USD
-2.98
4555.41 USD 4917.8 USD
Nasdaq US 700 Small Cap Index NQUS700SC 2078.81 USD
-0.4
2075.76 USD 2093.28 USD
Nasdaq AlphaDEX Multi Cap Growt NQDXUSMLTCG 2568.29 USD
+0.16
2566.7 USD 2581.47 USD